3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
88
Phase 1/2
24
Phase 1
19
Phase 3
11
Phase NA
8
Phase EARLY_PHASE1
5
Phase 2/3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Colorectal Neoplasms
13
Carcinoma, Hepatocellular
6
Colonic Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Uterine Cervical Neoplasms
2
Rectal Neoplasms
2
Ovarian Neoplasms
2
Fallopian Tube Neoplasms
2
Astrocytoma
2
Vipoma
1
Squamous Cell Carcinoma of Head and Neck
1
Spinal Cord Neoplasms
1
Somatostatinoma
1
Small Cell Lung Carcinoma
1
Recurrence
1
Progression Free Survival
1
Oropharyngeal Neoplasms
1
Oesophagogastric Cancer
1
Neuroendocrine Tumors
1
Neoplasms
1
Neoplasm Metastasis
1
Nasopharyngeal Carcinoma
1
Mouth Neoplasms
1
Mesothelioma
1
Lymphoid Interstitial Pneumonia
1
Lung Neoplasms
1
Laryngeal Neoplasms
1
Insulinoma
1
Inflammatory Breast Neoplasms
1
Hypopharyngeal Neoplasms
1
Interventions
Temozolomide
8
Lomustine
4
vocimagene amiretrorepvec
2
Radiation
2
veliparib
1
tinostamustine
1
regorafenib
1
carbon-11 acetate
1
antisecretory factor
1
Sunitinib
1
Standard of Care
1
Radiotherapy
1
Magnetic Resonance Spectroscopy
1
Irinotecan
1
GDC-0084
1
Flucytosine
1
Etoposide
1
Drug Therapy
1
Disulfiram
1
Dianhydrogalactitol
1
DNA
1
Copper
1
Carbon-11
1
Bevacizumab
1
Alkylating Agents
1
AZD1390
1
ADI PEG20
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Glioblastoma
×
Bevacizumab
×
Clear all
NCT02414165
2020-02-07
Toca5
Tocagen Inc.
Phase 2/3
Terminated
403 enrolled